1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | Panc-10.05; Panc10.05; PANC-10-05; PANC 1005; PANC1005; Panc1005; Pa16C; PL12; PL-12 |
| Species | Human |
| Cat.No | ABC-TC0900 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Pancreas |
| Disease | Adenocarinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Pancreas Cancer Cell Lines |
Panc 10.05 is an epithelial cell line derived from a primary pancreatic adenocarcinoma tumor located in the pancreatic head of a male patient in 1992. These cells are notable for harboring a K-ras oncogene mutation at codon 12, characterized by a GGT to GAT substitution resulting in the replacement of glycine with aspartic acid. Panc 10.05 cells exhibit tumorigenicity in nude or SCID mice and express the MHC class I surface antigen. They possess typical epithelial cell characteristics, marked by the expression of cytokeratin 7 and 18, and have been reported to have a plating efficiency of 40%.
Why choose Panc 10.05 from AcceGen?
Panc 10.05 cells are characterized by their exceptional viability and quality, cultivated under optimal conditions, and expertly cryopreserved. Rigorous quality control measures ensure their sterility and absence of mycoplasma contamination, with their identity confirmed via STR analysis.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
The Panc 10.05 cell line plays a pivotal role in advancing scientific research related to pancreatic ductal adenocarcinoma. It serves as a valuable tool for investigating strategies aimed at inhibiting cell proliferation and curtailing tumor growth in this aggressive cancer type. Furthermore, Panc 10.05 is instrumental in evaluating the efficacy of potential therapies for pancreatic ductal adenocarcinoma in vivo, including existing treatments targeting the K-ras oncogene mutation, thereby contributing to the development of novel therapeutic approaches in the fight against this challenging disease.
